Skip to main content
. Author manuscript; available in PMC: 2016 Apr 5.
Published in final edited form as: Science. 2016 Feb 5;351(6273):617–621. doi: 10.1126/science.aad3456

Fig. 4. MYK-461 suppresses hypertrophic and profibrotic gene programs in mouse models of HCM.

Fig. 4

(A) Heat map illustrating levels of gene expression in WT and treated and untreated HCM mice for 200 genes that are highly differentially regulated in HCM mice compared with WT mice. Genes are divided according to the cell type in which they are expressed (myocytes, fibroblasts, or both). Treatment with MYK-461 (2.5 mg/kg per day) began either before overt hypertrophy (early Rx) or after the development of hypertrophy (late Rx). (B) Heat map showing Pearson correlations between mouse genetic backgrounds and MYK-461 treatment regimens for 200 genes differentially regulated in untreated HCM mice. Statistical comparisons were performed between the Pearson correlations for WT animals or untreated mutants and each treatment condition for that mutant. Significance was assessed by Fisher r-to-z transformation (*P < 0.0001). (C) Fold change in gene expression levels (as compared with WT animals) for selected genes expressed in myocytes, fibroblasts, or both across MYK-461 treatment regimens in R453C mice (top) and R403Q mice (bottom; *P < 0.05).